LIVIVO - Search results -

Search results

Result 1 - 10 of total 33

Search options

Article: Antibiotics Clinical Development and Pipeline.

Hesterkamp, Thomas

Current topics in microbiology and immunology

2016 Volume 398, Page(s) 447–474

Abstract: There is a constant need for resupply with resistance-breaking antibiotics. Governmental programs and updated regulatory guidance have incentivized mainly small- and medium-sized biopharmaceutical companies to develop novel antibiotics up to market ... ...

Abstract	There is a constant need for resupply with resistance-breaking antibiotics. Governmental programs and updated regulatory guidance have incentivized mainly small- and medium-sized biopharmaceutical companies to develop novel antibiotics up to market licensure, while major pharma players, with exceptions, have abandoned the space for a perceived lack of a return on their investment. The portfolio of approved drugs has improved over recent years for gram-positive infections, including infections caused by methicillin-resistant Staphylococcus aureus. On the other hand, unmet medical need has surfaced in indications dominated by gram-negative pathogens including complicated intra-abdominal and bloodstream infections as well as hospital-acquired and ventilator-associated pneumonia. Few if any treatment options are left for extended-spectrum beta-lactamase- and carbapenemase-producing Enterobacteriaceae, e.g., Klebsiella pneumoniae, and the multi-drug-resistant non-fermenting gram-negative bacteria Pseudomonas aeruginosa and Acinetobacter baumannii. The present paper summarizes and reviews the clinical pipeline of novel antibiotics by clinical indication and identifies the unmet medical need in the space.
MeSH term(s)	Anti-Bacterial Agents/chemistry ; Anti-Bacterial Agents/pharmacology ; Bacteria/drug effects ; Bacteria/genetics ; Bacteria/metabolism ; Bacterial Infections/drug therapy ; Bacterial Infections/microbiology ; Drug Resistance, Multiple, Bacterial ; Humans
Chemical Substances	Anti-Bacterial Agents
Language	English
Publishing date	2016
Publishing country	Germany
Document type	Journal Article ; Review
ISSN	0070-217X
ISSN	0070-217X
DOI	10.1007/82_2015_451
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans.

Mayer, Leonie / Weskamm, Leonie M / Fathi, Anahita / Kono, Maya / Heidepriem, Jasmin / Krähling, Verena / Mellinghoff, Sibylle C / Ly, My Linh / Friedrich, Monika / Hardtke, Svenja / Borregaard, Saskia / Hesterkamp, Thomas / Loeffler, Felix F / Volz, Asisa / Sutter, Gerd / Becker, Stephan / Dahlke, Christine / Addo, Marylyn M

NPJ vaccines

2024 Volume 9, Issue 1, Page(s) 20

Abstract: In response to the COVID-19 pandemic, multiple vaccines were developed using platforms such as viral vectors and mRNA technology. Here, we report humoral and cellular immunogenicity data from human phase 1 clinical trials investigating two recombinant ... ...

Abstract	In response to the COVID-19 pandemic, multiple vaccines were developed using platforms such as viral vectors and mRNA technology. Here, we report humoral and cellular immunogenicity data from human phase 1 clinical trials investigating two recombinant Modified Vaccinia virus Ankara vaccine candidates, MVA-SARS-2-S and MVA-SARS-2-ST, encoding the native and the prefusion-stabilized SARS-CoV-2 spike protein, respectively. MVA-SARS-2-ST was more immunogenic than MVA-SARS-2-S, but both were less immunogenic compared to licensed mRNA- and ChAd-based vaccines in SARS-CoV-2 naïve individuals. In heterologous vaccination, previous MVA-SARS-2-S vaccination enhanced T cell functionality and MVA-SARS-2-ST boosted the frequency of T cells and S1-specific IgG levels when used as a third vaccination. While the vaccine candidate containing the prefusion-stabilized spike elicited predominantly S1-specific responses, immunity to the candidate with the native spike was skewed towards S2-specific responses. These data demonstrate how the spike antigen conformation, using the same viral vector, directly affects vaccine immunogenicity in humans.
Language	English
Publishing date	2024-01-26
Publishing country	England
Document type	Journal Article
ISSN	2059-0105
ISSN (online)	2059-0105
DOI	10.1038/s41541-023-00801-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: On the prediction of statistical parameters in high-throughput screening using resampling techniques.

Ilouga, Pierre E / Hesterkamp, Thomas

Journal of biomolecular screening

2012 Volume 17, Issue 6, Page(s) 705–712

Abstract: A severe drawback in the high-throughput screening (HTS) process is the unintentional (random) presence of false positives and negatives. Their rates depend, among others, on the screening process being applied and the target class. Although false ... ...

Abstract	A severe drawback in the high-throughput screening (HTS) process is the unintentional (random) presence of false positives and negatives. Their rates depend, among others, on the screening process being applied and the target class. Although false positives can be sorted out in subsequent process steps, their occurrence can lead to increased project cost. More fundamentally, it is not possible to rescue false nonhits. In this article, we investigate the prediction of the primary hit rate, hit confirmation rate, and false-positive and false-negative rates. Results for approximately 2800 compounds are considered that are tested as a pilot screen ahead of the primary screening work. This pilot screen is done at several concentrations and in replicates. The rates are predicted as a function of the proposed hit threshold by having the replicates serve as each other's confirmers, and confidence limits to the prediction are attached by means of a resampling scheme. A comparison of the rates resulting from the resampling with the primary hit rate and the confirmation rates obtained during the screening campaign shows how accurate this method is. Hence, the "optimal" compound concentration for the screen as well as the optimal hit threshold corresponding to low false rates can be determined prior to starting the subsequent screening campaign.
MeSH term(s)	Algorithms ; Drug Evaluation, Preclinical/methods ; Drug Evaluation, Preclinical/statistics & numerical data ; False Negative Reactions ; False Positive Reactions ; High-Throughput Screening Assays/methods ; High-Throughput Screening Assays/statistics & numerical data ; Monte Carlo Method ; Quality Control
Language	English
Publishing date	2012-07
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1433680-7
ISSN	1552-454X ; 1087-0571
ISSN (online)	1552-454X
ISSN	1087-0571
DOI	10.1177/1087057112441623
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4911: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pharmacokinetic and pharmacodynamic evaluation of the atypical tetracyclines chelocardin and amidochelocardin in murine infection models.

Rox, Katharina / Jansen, Rolf / Lukežič, Tadeja / Greweling-Pils, Marina / Herrmann, Jennifer / Miethke, Marcus / Hüttel, Stephan / Hennessen, Fabienne / Abou Fayad, Antoine / Holzhausen, Cornelia / Lundberg, Carina Vingsbo / Teague, Joanne / Sudarman, Enge / Bülter, Lisa / Hesterkamp, Thomas / Stadler, Marc / Brönstrup, Mark / Müller, Rolf

Microbiology spectrum

2023 Volume 12, Issue 1, Page(s) e0128923

Abstract: Importance: There is a strong need to find novel treatment options against urinary tract infections associated with antimicrobial resistance. This study evaluates two atypical tetracyclines, namely chelocardin (CHD) and amidochelocardin (CDCHD), with ... ...

Abstract	Importance: There is a strong need to find novel treatment options against urinary tract infections associated with antimicrobial resistance. This study evaluates two atypical tetracyclines, namely chelocardin (CHD) and amidochelocardin (CDCHD), with respect to their pharmacokinetics and pharmacodynamics. We show CHD and CDCHD are cleared at high concentrations in mouse urine. Especially, CDCHD is highly effective in an ascending urinary tract infection model, suggesting further preclinical evaluation.
MeSH term(s)	Animals ; Mice ; Microbial Sensitivity Tests ; Anti-Bacterial Agents/therapeutic use ; Anti-Bacterial Agents/pharmacokinetics ; Tetracyclines/pharmacology ; Tetracyclines/therapeutic use ; Urinary Tract Infections/drug therapy
Chemical Substances	chelocardin (N09QLW5PXU) ; Anti-Bacterial Agents ; Tetracyclines
Language	English
Publishing date	2023-12-04
Publishing country	United States
Document type	Journal Article
ZDB-ID	2807133-5
ISSN	2165-0497 ; 2165-0497
ISSN (online)	2165-0497
ISSN	2165-0497
DOI	10.1128/spectrum.01289-23
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: The RNA Polymerase Inhibitor Corallopyronin A Has a Lower Frequency of Resistance Than Rifampicin in

Balansky, Jan / Pfarr, Kenneth / Szekat, Christiane / Kehraus, Stefan / Aden, Tilman / Grosse, Miriam / Jansen, Rolf / Hesterkamp, Thomas / Schiefer, Andrea / König, Gabriele M / Stadler, Marc / Hoerauf, Achim / Bierbaum, Gabriele

Antibiotics (Basel, Switzerland)

2022 Volume 11, Issue 7

Abstract: Corallopyronin A (CorA) is active against Gram-positive bacteria and targets the switch region of RNA polymerase. Because of the high frequency of mutation (FoM) leading to rifampicin resistance, we determined the CorA FoM in S. aureus using fluctuation ... ...

Abstract	Corallopyronin A (CorA) is active against Gram-positive bacteria and targets the switch region of RNA polymerase. Because of the high frequency of mutation (FoM) leading to rifampicin resistance, we determined the CorA FoM in S. aureus using fluctuation analysis at 4 × minimum inhibitory concentration (MIC). Resistant mutants were characterized. S. aureus strains HG001, Mu50, N315, and USA300 had an MIC of 0.25 mg/L. The median FoM for CorA resistance was 1.5 × 10−8, 4.5-fold lower than the median FoM of 6.7 × 10−8 for rifampicin, and was reflected in a 4-fold lower mutation rate for CorA than rifampicin (6 × 10−9 for CorA vs. 2.5 × 10−8 for rifampicin). In CorA-resistant/rifampicin-sensitive strains, the majority of amino acid exchanges were S1127L in RpoB or K334N in RpoC. S. aureus Mu50, a rifampicin-resistant clinical isolate, yielded two further exchanges targeting amino acids L1131 and E1048 of the RpoB subunit. The plating of >1011 cells on agar containing a combination of 4 × MIC of rifampicin and 4 × MIC of CorA did not yield any growth. In conclusion, with proper usage, e.g., in combination therapy and good antibiotic stewardship, CorA is a potential antibiotic for treating S. aureus infections.
Language	English
Publishing date	2022-07-08
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics11070920
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Potent

Edwards, Jennifer L / Balthazar, Jacqueline T / Esposito, Danillo L A / Ayala, Julio C / Schiefer, Andrea / Pfarr, Kenneth / Hoerauf, Achim / Alt, Silke / Hesterkamp, Thomas / Grosse, Miriam / Stadler, Marc / Golparian, Daniel / Unemo, Magnus / Read, Timothy D / Shafer, William M

mSphere

2022 Volume 7, Issue 5, Page(s) e0036222

Abstract: Gonorrhea remains a major global public health problem because of the high incidence of infection (estimated 82 million cases in 2020) and the emergence and spread of Neisseria gonorrhoeae strains resistant to previous and current antibiotics used to ... ...

Abstract	Gonorrhea remains a major global public health problem because of the high incidence of infection (estimated 82 million cases in 2020) and the emergence and spread of Neisseria gonorrhoeae strains resistant to previous and current antibiotics used to treat infections. Given the dearth of new antibiotics that are likely to enter clinical practice in the near future, there is concern that cases of untreatable gonorrhea might emerge. In response to this crisis, the World Health Organization (WHO), in partnership with the Global Antibiotic Research and Development Partnership (GARDP), has made the search for and development of new antibiotics against N. gonorrhoeae a priority. Ideally, these antibiotics should also be active against other sexually transmitted organisms, such as Chlamydia trachomatis and/or Mycoplasma genitalium, which are often found with N. gonorrhoeae as co-infections. Corallopyronin A is a potent antimicrobial that exhibits activity against Chlamydia spp. and inhibits transcription by binding to the RpoB switch region. Accordingly, we tested the effectiveness of corallopyronin A against N. gonorrhoeae. We also examined the mutation frequency and modes of potential resistance against corallopyronin A. We report that corallopyronin A has potent antimicrobial action against antibiotic-susceptible and antibiotic-resistant N. gonorrhoeae strains and could eradicate gonococcal infection of cultured, primary human cervical epithelial cells. Critically, we found that spontaneous corallopyronin A-resistant mutants of N. gonorrhoeae are exceedingly rare (≤10
MeSH term(s)	Humans ; Gonorrhea/drug therapy ; Gonorrhea/prevention & control ; Coinfection ; Neisseria gonorrhoeae/genetics ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Chlamydia trachomatis ; Anti-Infective Agents/pharmacology
Chemical Substances	corallopyronin A ; Anti-Bacterial Agents ; Anti-Infective Agents
Language	English
Publishing date	2022-09-12
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, Non-U.S. Gov't
ISSN	2379-5042
ISSN (online)	2379-5042
DOI	10.1128/msphere.00362-22
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: In Vitro-In Vivo Relationship in Mini-Scale-Enabling Formulations of Corallopyronin A.

Becker, Tim / Krome, Anna K / Vahdati, Sahel / Schiefer, Andrea / Pfarr, Kenneth / Ehrens, Alexandra / Aden, Tilman / Grosse, Miriam / Jansen, Rolf / Alt, Silke / Hesterkamp, Thomas / Stadler, Marc / Hübner, Marc P / Kehraus, Stefan / König, Gabriele M / Hoerauf, Achim / Wagner, Karl G

Pharmaceutics

2022 Volume 14, Issue 8

Abstract: In vivo studies in mice provide a valuable model to test novel active pharmaceutical ingredients due to their low material need and the fact that mice are frequently used as a species for early efficacy models. However, preclinical in vitro evaluations ... ...

Abstract	In vivo studies in mice provide a valuable model to test novel active pharmaceutical ingredients due to their low material need and the fact that mice are frequently used as a species for early efficacy models. However, preclinical in vitro evaluations of formulation principles in mice are still lacking. The development of novel in vitro and in silico models supported the preclinical formulation evaluation for the anti-infective corallopyronin A (CorA). To this end, CorA and solubility-enhanced amorphous solid dispersion formulations, comprising povidone or copovidone, were evaluated regarding biorelevant solubilities and dissolution in mouse-specific media. As an acidic compound, CorA and CorA-ASD formulations showed decreased solubilities in mice when compared with human-specific media. In biorelevant biphasic dissolution experiments CorA-povidone showed a three-fold higher fraction partitioned into the organic phase of the biphasic dissolution, when compared with CorA-copovidone. Bioavailabilities determined by pharmacokinetic studies in BALB/c mice correlated with the biphasic dissolution prediction and resulted in a Level C in vitro-in vivo correlation. In vitro cell experiments excluded intestinal efflux by P-glycoprotein or breast cancer resistance protein. By incorporating in vitro results into a physiologically based pharmacokinetic model, the plasma concentrations of CorA-ASD formulations were predicted and identified dissolution as the limiting factor for bioavailability.
Language	English
Publishing date	2022-08-09
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527217-2
ISSN	1999-4923
ISSN	1999-4923
DOI	10.3390/pharmaceutics14081657
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Corallopyronin A: antimicrobial discovery to preclinical development.

Krome, Anna K / Becker, Tim / Kehraus, Stefan / Schiefer, Andrea / Gütschow, Michael / Chaverra-Muñoz, Lillibeth / Hüttel, Stephan / Jansen, Rolf / Stadler, Marc / Ehrens, Alexandra / Pogorevc, Domen / Müller, Rolf / Hübner, Marc P / Hesterkamp, Thomas / Pfarr, Kenneth / Hoerauf, Achim / Wagner, Karl G / König, Gabriele M

Natural product reports

2022 Volume 39, Issue 9, Page(s) 1705–1720

Abstract: Covering: August 1984 up to January 2022Worldwide, increasing morbidity and mortality due to antibiotic-resistant microbial infections has been observed. Therefore, better prevention and control of infectious diseases, as well as appropriate use of ... ...

Abstract	Covering: August 1984 up to January 2022Worldwide, increasing morbidity and mortality due to antibiotic-resistant microbial infections has been observed. Therefore, better prevention and control of infectious diseases, as well as appropriate use of approved antibacterial drugs are crucial. There is also an urgent need for the continuous development and supply of novel antibiotics. Thus, identifying new antibiotics and their further development is once again a priority of natural product research. The antibiotic corallopyronin A was discovered in the 1980s in the culture broth of the Myxobacterium
MeSH term(s)	Anti-Bacterial Agents/pharmacology ; Anti-Infective Agents/pharmacology ; Biological Products/pharmacology ; Humans ; Lactones ; Water
Chemical Substances	Anti-Bacterial Agents ; Anti-Infective Agents ; Biological Products ; Lactones ; corallopyronin A ; Water (059QF0KO0R)
Language	English
Publishing date	2022-09-21
Publishing country	England
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	2002546-4
ISSN	1460-4752 ; 0265-0568
ISSN (online)	1460-4752
ISSN	0265-0568
DOI	10.1039/d2np00012a
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Fragment-based activity space: smaller is better.

Hesterkamp, Thomas / Whittaker, Mark

Current opinion in chemical biology

2008 Volume 12, Issue 3, Page(s) 260–268

Abstract: Fragment-based drug discovery has the potential to supersede traditional high throughput screening based drug discovery for molecular targets amenable to structure determination. This is because the chemical diversity coverage is better accomplished by a ...

Abstract	Fragment-based drug discovery has the potential to supersede traditional high throughput screening based drug discovery for molecular targets amenable to structure determination. This is because the chemical diversity coverage is better accomplished by a fragment collection of reasonable size than by larger HTS collections. Furthermore, fragments have the potential to be efficient target binders with higher probability than more elaborated drug-like compounds. The selection of the fragment screening technique is driven by sensitivity and throughput considerations, and we advocate in the present article the use of high concentration bioassays in conjunction with NMR-based hit confirmation. Subsequent ligand X-ray structure determination of the fragment ligand in complex with the target protein by co-crystallisation or crystal soaking can focus on confirmed binders.
MeSH term(s)	Biological Assay ; Crystallography, X-Ray ; Drug Evaluation, Preclinical/methods ; Magnetic Resonance Spectroscopy ; Pharmaceutical Preparations/chemistry
Chemical Substances	Pharmaceutical Preparations
Language	English
Publishing date	2008-06
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1439176-4
ISSN	1879-0402 ; 1367-5931
ISSN (online)	1879-0402
ISSN	1367-5931
DOI	10.1016/j.cbpa.2008.02.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4986: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Corallopyronin A: antimicrobial discovery to preclinical development

Krome, Anna K. / Becker, Tim / Kehraus, Stefan / Schiefer, Andrea / Gütschow, Michael / Chaverra-Muñoz, Lillibeth / Hüttel, Stephan / Jansen, Rolf / Stadler, Marc / Ehrens, Alexandra / Pogorevc, Domen / Müller, Rolf / Hübner, Marc P. / Hesterkamp, Thomas / Pfarr, Kenneth / Hoerauf, Achim / Wagner, Karl G. / König, Gabriele M.

Natural product reports. 2022 Sept. 21, v. 39, no. 9

2022

Abstract: Worldwide, increasing morbidity and mortality due to antibiotic-resistant microbial infections has been observed. Therefore, better prevention and control of infectious diseases, as well as appropriate use of approved antibacterial drugs are crucial. ... ...

Abstract	Worldwide, increasing morbidity and mortality due to antibiotic-resistant microbial infections has been observed. Therefore, better prevention and control of infectious diseases, as well as appropriate use of approved antibacterial drugs are crucial. There is also an urgent need for the continuous development and supply of novel antibiotics. Thus, identifying new antibiotics and their further development is once again a priority of natural product research. The antibiotic corallopyronin A was discovered in the 1980s in the culture broth of the Myxobacterium Corallococcus coralloides and serves, in the context of this review, as a show case for the development of a naturally occurring antibiotic compound. The review demonstrates how a hard to obtain, barely water soluble and unstable compound such as corallopyronin A can be developed making use of sophisticated production and formulation approaches. Corallopyronin A is a bacterial DNA-dependent RNA polymerase inhibitor with a new target site and one of the few representatives of this class currently in preclinical development. Efficacy against Gram-positive and Gram-negative pathogens, e.g., Chlamydia trachomatis, Orientia tsutsugamushi, Staphylococcus aureus, and Wolbachia has been demonstrated. Due to its highly effective in vivo depletion of Wolbachia, which are essential endobacteria of most filarial nematode species, and its robust macrofilaricidal efficacy, corallopyronin A was selected as a preclinical candidate for the treatment of human filarial infections. This review highlights the discovery and production optimization approaches for corallopyronin A, as well as, recent preclinical efficacy results demonstrating a robust macrofilaricidal effect of the anti-Wolbachia candidate, and the solid formulation strategy which enhances the stability as well as the bioavailability of corallopyronin A.
Keywords	Chlamydia trachomatis ; Corallococcus ; DNA-directed RNA polymerase ; Nematoda ; Orientia tsutsugamushi ; Staphylococcus aureus ; Wolbachia ; antibiotic resistance ; antibiotics ; bioavailability ; culture media ; humans ; morbidity ; mortality ; myxobacteria ; water solubility
Language	English
Dates of publication	2022-0921
Size	p. 1705-1720.
Publishing place	The Royal Society of Chemistry
Document type	Article
ZDB-ID	2002546-4
ISSN	1460-4752 ; 0265-0568
ISSN (online)	1460-4752
ISSN	0265-0568
DOI	10.1039/d2np00012a
Database	NAL-Catalogue (AGRICOLA)

Order via subito

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito